Video Experimental Relacionado
Updated: Jul 1, 2025
07:59
Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
1.1K
Trayectorias evolutivas del cáncer de pulmón de células pequeñas bajo tratamiento
Julie George1,2, Lukas Maas3, Nima Abedpour3,4,5
1Department of Translational Genomics, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany. jgeorge@uni-koeln.de.
Nature
|March 14, 2024
Resumen
La evolución genómica en el cáncer de pulmón de células pequeñas (SCLC) conduce a una recaída rápida después de la quimioterapia. Comprender estos patrones evolutivos es clave para desarrollar nuevos tratamientos para este cáncer agresivo.
Área de la Ciencia:
- En el campo de la oncología
- La genómica
- Evolución del cáncer
Sus antecedentes:
- El cáncer de pulmón de células pequeñas (SCLC) es muy sensible a la quimioterapia, pero a menudo recae rápidamente.
- Los mecanismos evolutivos detrás de la respuesta del SCLC al tratamiento y la recaída siguen sin estar claros.
Objetivo del estudio:
- Investigar los procesos evolutivos genómicos del CPCL durante la quimioterapia y la inmunoterapia.
- Identificar los orígenes clonales de la recaída y los patrones genómicos asociados con la sensibilidad y la resistencia al tratamiento.
Principales métodos:
- Secuenciación multirregional de 160 tumores de SCLC de 65 pacientes en el momento del diagnóstico y durante el tratamiento.
- Análisis filogenético para reconstruir la evolución del tumor bajo terapia.
Principales resultados:
- La quimioterapia indujo una heterogeneidad intratumoral genómica significativa y una diversidad clonal espacial en el CPCM.
- La recaída del tumor fue impulsada por la evolución ramificada y la reexpansión de los clones ancestrales.
- Las alteraciones de TP53/RB1 fueron eventos ancestrales comunes, mientras que las amplificaciones de MYC fueron a menudo subclonales.
- Las alteraciones y co-mutaciones específicas de TP53 (TP73, CREBBP/ EP300, FMN2) se correlacionaron con tiempos de recaída más cortos.
Conclusiones:
- El clon del antepasado común es una fuente primaria de diversidad clonal en la recaída del CPCM.
- La evolución genómica bajo terapia revela patrones clave de sensibilidad y resistencia al SCLC.
- La comprensión de estas dinámicas evolutivas puede informar futuras estrategias terapéuticas para el CPCM.
Más Videos Relacionados
09:38Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019
8.0K
06:11Therapy Testing in a Spheroid-based 3D Cell Culture Model for Head and Neck Squamous Cell Carcinoma
Published on: April 20, 2018
9.8K
Videos de Conceptos Relacionados
02:57Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
02:50Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
02:49Cancer Therapies
7.7K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.7K
02:07Tumor Progression
6.3K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.3K
02:53Adaptive Mechanisms in Cancer Cells
5.8K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
5.8K
02:56Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K